ABIVAX is trading 4.71% up at €87.80, with no specific catalyst confirmed for the September 30, 2026 move.
- On September 30, the company announced it will present obefazimod data at United European Gastroenterology Week 2026; available sources do not establish that this caused the move.
- A recent BTIG Buy rating and $175 target also did not clearly explain the share-price move.